1 / 1

Supplementary Figure 3

HCT116. HCT116-TP53KO. NT. 5FU. Ox. NT. 5FU. Ox. 5. 2. 4. LC3. 3. IC50 5FU (µM). 1. IC50 Oxaliplatin (µM). 2. 1. GAPDH. 0. 0. HCT116. HCT116 TP53KO. HCT116. HCT116 TP53KO. 6. 5. 4. 7. HCT116. IC50 5FU (µM). 3. 6. HCT116. 0.4. 2. 5. 4. 1. 0.3. IC50 5FU (µM).

august-curry
Télécharger la présentation

Supplementary Figure 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HCT116 HCT116-TP53KO NT 5FU Ox NT 5FU Ox 5 2 4 LC3 3 IC50 5FU (µM) 1 IC50 Oxaliplatin (µM) 2 1 GAPDH 0 0 HCT116 HCT116 TP53KO HCT116 HCT116 TP53KO 6 5 4 7 HCT116 IC50 5FU (µM) 3 6 HCT116 0.4 2 5 4 1 0.3 IC50 5FU (µM) 3 IC50 Oxaliplatin (µM) 0 0.2 1.6 siLUC siATG5 si ATG7 2 1.4 1 0.1 1.2 0 1 0 siLUC siATG5 si ATG7 IC50 Oxaliplatin (µM) 0.8 siLUC si ATG5 si ATG7 0.6 0.4 0.2 0 siLUC si ATG5 si ATG7 HCT116-TP53KO HCT116-TP53KO Supplementary Figure 3 A B D C E F

More Related